1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
VolitionRX prepaid in cash the outstanding principal of its $7.5 million senior secured convertible note issued to Lind Global Asset Management XII LLC, with the prepayment made on September 11, 2026, and the company says no further amounts remain outstanding under that note. The company says the prepayment prevents further potential dilution to stockholders from the note, and the separate $2.4 million 2026 Note remains in effect.
Prepayment of approximately $422,000 made September 11, 2026 under Section 1.4.1 of the 2025 Note
The $7.5 million 2025 Note, dated May 20, 2025, is fully satisfied; the 2026 Note remains outstanding at $2,041,667 per the press release
CEO Cameron Reynolds said the note was retired more than eight months ahead of its originally scheduled maturity
The FDA approved Biofrontera's supplemental New Drug Application for Ameluz with the BF-RhodoLED lamp for superficial basal cell carcinoma in adults. The company says this makes Ameluz the first and only photodynamic therapy approved by the FDA for a skin cancer, and that it expands the addressable market. The filing gives no revenue, sales or financial impact figures.
FDA approval announced September 14, 2026 for Ameluz with BF-RhodoLED lamp for superficial basal cell carcinoma in adults
Phase 3 trial in 187 adults: 66% (95 of 145) of Ameluz PDT subjects achieved the primary endpoint versus 5% (2 of 42) on placebo-PDT
Company plans an official launch of the new indication late in Q4 2026 through Q1 2027, using its existing commercial organization and lamp base
The Baldwin Insurance Group agreed to be acquired by an entity formed by Sequence Holdings and DFO Management, the Dell family investment office, in an all-cash deal. Shareholders would receive $32.50 per share, and the transaction implies a total enterprise value of about $7.7 billion, including about $3.1 billion of net debt. The deal requires shareholder and regulatory approvals and is expected to close in Q1 2027, after which Baldwin shares would stop trading on Nasdaq.
Shareholders to receive $32.50 per share in cash, a premium of about 88% to the unaffected closing price on June 17, 2026
Equity purchase price of about $4.6 billion and total enterprise value of about $7.7 billion, implying about 20x trailing-twelve-month Adjusted EBITDA of about $396 million
Expected close in Q1 2027, subject to shareholder approval, regulatory approvals and other customary conditions
Shares would be delisted from Nasdaq and deregistered under the Exchange Act after the effective time
Immersion reported first-quarter fiscal 2027 results for the three months ended July 31, 2026, with total revenues of $294.4 million, up from $292.0 million a year earlier, and GAAP net income attributable to Immersion stockholders of $4.9 million, or $0.17 per diluted share, versus a loss of $0.9 million a year earlier. Non-GAAP net income attributable to Immersion stockholders was $16.6 million, or $0.50 per diluted share, slightly below $0.52 a year earlier. The Board also declared a quarterly dividend of $0.075 per share payable October 30, 2026.
Total revenues of $294.4 million vs. $292.0 million in the same quarter last year; the consolidated figures include Barnes & Noble Education
GAAP net income attributable to Immersion stockholders of $4.9 million, or $0.17 per diluted share, vs. a loss of $(0.9) million, or $(0.03) per share, a year earlier
Non-GAAP net income attributable to Immersion stockholders of $16.6 million, or $0.50 per diluted share, vs. $16.9 million, or $0.52, a year earlier
Quarterly cash dividend of $0.075 per share payable October 30, 2026, to holders of record on October 16, 2026
SmartKem, Inc. received notice from Nasdaq on September 10, 2026 that it has regained compliance with the $1.00 minimum bid price requirement, and the Staff has closed the matter. The company had received a deficiency notice on March 5, 2026, so the stock has avoided a listing-related threat that had been pending since then.
Nasdaq Staff notified SmartKem on September 10, 2026 that it regained compliance with Listing Rule 5550(a)(2).
The closing bid price was at or above $1.00 per share for 13 consecutive business days, from August 21 through September 9, 2026.
The company first received the minimum bid price notice from Nasdaq on March 5, 2026.
In a Regulation FD filing tied to the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026, Bionano presented Q2 2026 results showing revenue of $8.2 million, above its $7.5 million to $7.8 million guidance and up 21% from Q2 2025. The company raised the lower end of its FY26 revenue guidance to $31 million to $33 million from $30 million to $33 million, and it projects FY27 revenue of $50 million to $54 million. The filing also repeats that the company's ability to continue as a going concern depends on obtaining significant additional financing.
Q2 2026 revenue was $8.2 million, above guidance of $7.5 million to $7.8 million and up 21% from Q2 2025.
FY26 revenue guidance is $31 million to $33 million, with the lower end raised from $30 million.
FY27 revenue outlook is $50 million to $54 million, with adjusted EBITDA projected at about $0 in the Q4 FY27 exit rate.
The company disclosed that its ability to continue as a going concern requires significant additional financing.
RF Industries reported third-quarter fiscal 2026 results for the period ended July 31, 2026, with net sales of $23.96 million, up 21% from $19.79 million a year earlier. Consolidated net income was $1.44 million, or $0.12 per diluted share, compared with $392,000, or $0.04, in the prior-year quarter. For shareholders, the filing shows higher sales, operating income and profit, though the 8-K does not include guidance.
Net sales $23.96 million, up 21% year over year and up 16% from $20.7 million in the second quarter of fiscal 2026
Gross profit margin 35.6%, up from 34% in the prior-year quarter; operating income $1.8 million versus $720,000
Consolidated net income $1.44 million, or $0.12 per diluted share, versus $0.04; non-GAAP EPS $0.19 versus $0.10
Backlog $18.6 million at July 31, 2026, and $19.8 million as of September 14, 2026
Definium Therapeutics announced positive topline results from Panorama, its second Phase 3 study of DT120 ODT in generalized anxiety disorder, meeting its primary endpoint and all key secondary endpoints. The filing also posted a presentation on the company website, and the company plans a pre-NDA meeting with the FDA in 4Q 2026 and an NDA filing in 1H 2027.
Primary endpoint met: placebo-adjusted HAM-A change of 5.1 points at Week 12 for the 100 µg dose (p<0.0001), with 96 participants in the 100 µg group and 97 on placebo
Company reports the drug was generally well tolerated, with no drug-related serious adverse events and no new safety signals identified
Pre-NDA meeting scheduled for 4Q 2026; NDA filing anticipated in 1H 2027
Webcast to review results held at 8:00 a.m. EDT on September 14, 2026
Cabaletta Bio said holders exercised warrants from its June 2025 underwritten public offering, bringing aggregate gross proceeds to approximately $128.2 million through the September 12, 2026 expiration date. Most of that total, 46,011,900 warrants for approximately $115.0 million, was exercised from July 1, 2026 through expiration. For shareholders, the exercises add cash to the company at a fixed exercise price of $2.50 per share.
Warrants issued in the June 2025 offering: 53,090,190, each with an exercise price of $2.50 per whole share
From July 1, 2026 through September 12, 2026: 46,011,900 warrants exercised for approximately $115.0 million in gross proceeds
Total gross proceeds from exercises through the expiration date: approximately $128.2 million, including $13.2 million from 5,275,100 warrants exercised through June 30, 2026
On September 11, 2026, Scholar Rock Holding Corporation announced that the FDA approved ISEMBYLD (apitegromab-mstn) for spinal muscular atrophy in adults and children 2 years of age and older who are receiving an SMN2-targeted treatment. The company said the U.S. commercial launch is underway, with product available to ship in the coming days, and it received a Rare Pediatric Disease Priority Review Voucher with the approval.
Phase 3 SAPPHIRE study: 2.2-point HFMSE motor function improvement vs. placebo at one year (nominal p=0.0121)
34.2% of ISEMBYLD-treated patients showed a 3-point or greater HFMSE increase vs. 13.5% on placebo
Fractures occurred in 9% of ISEMBYLD 10 mg/kg patients vs. 2% on placebo; the label notes an increased fracture risk
Management webcast and conference call on September 14, 2026, at 8:00 a.m. ET; cash and securities were $492 million as of June 30, 2026
The FDA granted Breakthrough Therapy designation to Armata's AP-SA02, an intravenous multi-phage product candidate for adjunct treatment of complicated Staphylococcus aureus bacteremia. The company says the designation is intended to expedite review and that AP-SA02 now holds Breakthrough Therapy, Fast Track and QIDP designations, but the filing discloses no revenue, earnings or financing figures.
FDA granted Breakthrough Therapy designation to AP-SA02 for complicated bacteremia caused by MSSA or MRSA, announced September 14, 2026.
AP-SA02 now holds Breakthrough Therapy, Fast Track and QIDP designations.
In the Phase 1b/2a diSArm study, 100% of AP-SA02 patients maintained clinical response without relapse at 28 days after completion of BAT, compared with 75% on placebo plus BAT.
The company plans a Phase 3 superiority study, anticipated to start in the second half of 2026.
Corbus Pharmaceuticals announced positive topline results from its 16-week CANYON-1 Phase 1b trial of oral CRB-913 for obesity, showing statistically significant weight loss at all three doses, with the 60 mg dose producing a mean 5.0% weight loss at 12 weeks versus placebo. The data will be presented as a late-breaking abstract at ObesityWeek 2026, and the company plans to engage with the FDA and start a Phase 2 monotherapy study in the first half of 2027. The filing reports no revenue or profit figures, and the results come from a small early-stage trial with cross-trial safety comparisons that the company itself notes are not head-to-head.
60 mg cohort (n=62) showed 5.0% mean weight loss at week 12 versus 0.0% for placebo (n=66), p<0.0001
Treatment discontinuations due to adverse events were 3.1% to 13.1% for CRB-913, versus 6.9% to 20.7% for approved oral GLP-1 drugs, per cross-trial comparison
Data to be presented at ObesityWeek 2026, November 14 to 17, 2026; Phase 2 monotherapy study expected to start in first half of 2027
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.